By Priya Venkatesan The REPRIEVE trial has shown a benefit of statins in reducing the risk of cardiovascular events in people living with HIV, but many […]
Abstract Objective Skeletal muscle quality and mass are important for maintaining physical function during advancing age. We leveraged baseline data from REPRIEVE to evaluate whether paraspinal muscle density […]
By Emily Harris People with HIV and a low to moderate traditional risk of cardiovascular disease who took a daily 4-mg dose of pitavastatin reduced their risk […]
By Megan Brooks An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong […]
By Shelley Wood HIV is merely a “risk modifier” in current guidelines; these results pave the way for a new primary-prevention indication for statins. Read the […]
Abstract Background Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and […]
By Barbara Jungwirth People living with HIV (PLWH) taking integrase strand transfer inhibitors (INSTIs) gained more weight during the first two years of that regimen than […]